Cyclopharm (CYC) Stock Overview
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CYC Community Fair Values
Create NarrativeSee what 16 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Cyclopharm Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.60 |
| 52 Week High | AU$1.29 |
| 52 Week Low | AU$0.56 |
| Beta | 0.60 |
| 1 Month Change | -28.40% |
| 3 Month Change | -21.43% |
| 1 Year Change | -43.46% |
| 3 Year Change | -68.24% |
| 5 Year Change | -77.34% |
| Change since IPO | -67.73% |
Recent News & Updates
CYC: Modest Assumption Shifts Will Support Future Upside Potential
Analysts have slightly adjusted their price target for Cyclopharm, citing updated fair value, discount rate, profit margin and P/E assumptions. Together, these factors point to a modest recalibration of the stock's A$ valuation rather than a major shift in outlook.CYC: Follow On Equity Offering Will Support Future Upside Potential
Analysts have kept their A$ fair value estimate for Cyclopharm effectively unchanged, with only small adjustments to the discount rate, profit margin, and future P/E assumptions, resulting in a modest change to the price target. What's in the News Cyclopharm completed a follow on equity offering of A$0.182492 million in ordinary shares.CYC: Follow On Equity Offerings Will Support Future Upside Potential
The updated analyst price target for Cyclopharm has been reduced to A$1.00 from A$1.49. Analysts cite a lower revenue growth outlook of 16.42% and a higher assumed discount rate of 7.81%, partly offset by a slightly higher profit margin of 9.77% and a P/E assumption of 37.02x.Recent updates
CYC: Modest Assumption Shifts Will Support Future Upside Potential
Analysts have slightly adjusted their price target for Cyclopharm, citing updated fair value, discount rate, profit margin and P/E assumptions. Together, these factors point to a modest recalibration of the stock's A$ valuation rather than a major shift in outlook.CYC: Follow On Equity Offering Will Support Future Upside Potential
Analysts have kept their A$ fair value estimate for Cyclopharm effectively unchanged, with only small adjustments to the discount rate, profit margin, and future P/E assumptions, resulting in a modest change to the price target. What's in the News Cyclopharm completed a follow on equity offering of A$0.182492 million in ordinary shares.CYC: Follow On Equity Offerings Will Support Future Upside Potential
The updated analyst price target for Cyclopharm has been reduced to A$1.00 from A$1.49. Analysts cite a lower revenue growth outlook of 16.42% and a higher assumed discount rate of 7.81%, partly offset by a slightly higher profit margin of 9.77% and a P/E assumption of 37.02x.Cyclopharm Limited's (ASX:CYC) Price Is Right But Growth Is Lacking After Shares Rocket 28%
Cyclopharm Limited ( ASX:CYC ) shares have had a really impressive month, gaining 28% after a shaky period beforehand...Benign Growth For Cyclopharm Limited (ASX:CYC) Underpins Stock's 29% Plummet
Unfortunately for some shareholders, the Cyclopharm Limited ( ASX:CYC ) share price has dived 29% in the last thirty...US Healthcare Trends Will Accelerate Advanced Technegas Integration
Key Takeaways U.S. market traction, rising respiratory disease demand, and updated guidelines position the company for strong recurring revenue and margin expansion via Technegas adoption. Operational leverage from earlier investments and expanding Technegas indications drive volume growth, improved earnings, and higher annuity-like income streams.With A 38% Price Drop For Cyclopharm Limited (ASX:CYC) You'll Still Get What You Pay For
Cyclopharm Limited ( ASX:CYC ) shares have had a horrible month, losing 38% after a relatively good period beforehand...Here's Why We're Not Too Worried About Cyclopharm's (ASX:CYC) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Cyclopharm Limited (ASX:CYC) Not Flying Under The Radar
When close to half the companies in the Medical Equipment industry in Australia have price-to-sales ratios (or "P/S...What You Can Learn From Cyclopharm Limited's (ASX:CYC) P/SAfter Its 26% Share Price Crash
Cyclopharm Limited ( ASX:CYC ) shares have had a horrible month, losing 26% after a relatively good period beforehand...Is Cyclopharm Limited (ASX:CYC) Trading At A 25% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Cyclopharm fair value estimate is AU$2.92 Cyclopharm is...Companies Like Cyclopharm (ASX:CYC) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Companies Like Cyclopharm (ASX:CYC) Can Afford To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although...Companies Like Cyclopharm (ASX:CYC) Can Afford To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Analyst Forecasts For Cyclopharm Limited (ASX:CYC) Are Surging Higher
Celebrations may be in order for Cyclopharm Limited ( ASX:CYC ) shareholders, with the analysts delivering a...Here's Why We're Not At All Concerned With Cyclopharm's (ASX:CYC) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...We Think Cyclopharm (ASX:CYC) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Cyclopharm Limited's (ASX:CYC) Analyst Just Slashed This Year's Estimates
One thing we could say about the covering analyst on Cyclopharm Limited ( ASX:CYC ) - they aren't optimistic, having...Shareholders Will Probably Hold Off On Increasing Cyclopharm Limited's (ASX:CYC) CEO Compensation For The Time Being
The share price of Cyclopharm Limited ( ASX:CYC ) has increased significantly over the past few years. However, the...Rainbows and Unicorns: The Cyclopharm Limited (ASX:CYC) Analyst Just Became A Lot More Optimistic
Shareholders in Cyclopharm Limited ( ASX:CYC ) may be thrilled to learn that the covering analyst has just delivered a...Cyclopharm (ASX:CYC) Has Rewarded Shareholders With An Exceptional 401% Total Return On Their Investment
Long term investing can be life changing when you buy and hold the truly great businesses. And we've seen some truly...Is Cyclopharm Limited (ASX:CYC) Popular Amongst Insiders?
A look at the shareholders of Cyclopharm Limited ( ASX:CYC ) can tell us which group is most powerful. Insiders often...We're Not Very Worried About Cyclopharm's (ASX:CYC) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, Cyclopharm...Shareholder Returns
| CYC | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | -10.4% | 2.4% | -1.1% |
| 1Y | -43.5% | -43.3% | 0.1% |
Return vs Industry: CYC matched the Australian Medical Equipment industry which returned -43.3% over the past year.
Return vs Market: CYC underperformed the Australian Market which returned 0.1% over the past year.
Price Volatility
| CYC volatility | |
|---|---|
| CYC Average Weekly Movement | 9.7% |
| Medical Equipment Industry Average Movement | 10.2% |
| Market Average Movement | 10.2% |
| 10% most volatile stocks in AU Market | 17.2% |
| 10% least volatile stocks in AU Market | 4.1% |
Stable Share Price: CYC has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: CYC's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 109 | James McBrayer | www.cyclomedica.com/company/cyclopharm/ |
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, the United States, and internationally. The company operates Technegas which offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. It is also involved in the research and development; and distribution of third-party products to the diagnostic imaging sector.
Cyclopharm Limited Fundamentals Summary
| CYC fundamental statistics | |
|---|---|
| Market cap | AU$79.42m |
| Earnings (TTM) | -AU$17.22m |
| Revenue (TTM) | AU$32.33m |
Is CYC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CYC income statement (TTM) | |
|---|---|
| Revenue | AU$32.33m |
| Cost of Revenue | AU$14.47m |
| Gross Profit | AU$17.85m |
| Other Expenses | AU$35.07m |
| Earnings | -AU$17.22m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.14 |
| Gross Margin | 55.23% |
| Net Profit Margin | -53.27% |
| Debt/Equity Ratio | 0% |
How did CYC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/09 10:55 |
| End of Day Share Price | 2026/06/09 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cyclopharm Limited is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Hester | Bell Potter |